Early research (Phase 1)Looking for participantsNCT03692429
What this trial is testing
AlloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Who this might be right for
Unresectable Metastatic Colorectal Cancer
Celyad Oncology SA 49